BOSTON, July 15, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the opening of new 10,000 square foot laboratory and office space in Framingham, Massachusetts. This new space will allow Nirogy to create up to 35 new jobs of highly skilled biotech positions.
From left to right: Dennis McWilliams/Sante, Vincent Sandanayaka/Nirogy, Ron DePinho/Sporos, Peter Feinberg/Sporos.
“As Nirogy expands, we want to ensure that our research benefits from all of the available resources in the biotech industry as we strategically position ourselves in a vibrant and world-renowned biotech region. Our expansion serves to accelerate our potential to advance current programs to the clinic and provides new opportunities to attract top-tier talent to the team. The move into a larger space is a critical milestone in our growth to realize our vision of creating a path to end patient suffering and we thank everyone who helped us reach this point,” stated Vincent Sandanayaka, Ph.D., founder and CEO of Nirogy.
This new space houses sophisticated biotechnology and scientific equipment to expand operations as well as administrative offices. Nirogy recently opened the new facility with a ribbon-cutting ceremony attended by management and key stakeholders and plans to significantly increase the headcount to fill the space in the coming months.
Nirogy Therapeutics is a biotechnology company based in Boston, MA, developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.